mobile Health Forschung

Datenqualität auf akademischem Standard

In Zusammenarbeit mit Krebsforschungszentren, Kliniken und dem Life Sciences Bereich engagieren wir uns für Patienten-Empowerment (Mitwirkung und Mitentscheidung im Gesundheitsbereich) und Datenerhebung auf regulatorischem Studienniveau. Die von Patient*innen erhobenen Symptome in Verbindung mit klinischen Daten eröffnen dabei  neue Erkenntnisse und Möglichkeiten für die medizinische Versorgung und Forschung (real-world evidence).

Mehr als 1000 Patient*innen sind bereits mit unserem System verbunden.

So wird die Entwicklung neuer, gezielter Methoden zur Behandlung von Krebs und Krankheiten ermöglicht.

MobileHealth-Network-Parts_Patient

Als Patient*in

Sie unterstützen die Krebsforschung, indem Sie Ihre Daten in der App in pseudonymisierter Form freigeben. So tragen Sie mit Ihrer Patientenerfahrung zur Verbesserung der Behandlung bei – selbstverständlich freiwillig.

MobileHealth-Network-Parts-Arzt

Als Ärzt*in

Sie unterstützen die Krebsforschung, indem Sie Ihre Patient*innen bei der Nutzung der App unterstützen und sich an eHealth-Studien und Registern beteiligen.

MobileHealth-Network-Parts-Hospital

Co-Creation

Zusammen neue Forschungsansätze initiieren – Sie haben eine Idee? Wir die nötigen Tools, Kontakte und Erfahrung. 

Studies and Publications

    • Proprietary Consilium Care Platform & App

CE-Mark Class I (MDD Class I)

Enables symptom progression tracking and CTCAE-based notifications to patients and oncologists.

    • Clinical Trial: Patient-App Improves Daily Activity

Randomized trial in 140 breast cancer patients undergoing chemotherapy

📰 Published in JMIR 2016

🔗 PubMed: 27601354

    • Collaboration with SAKK – Alpine Tumor Immunology Registry (TIR)

Symptom recording in 150 patients undergoing immunotherapy

📰 SAKK Trial Link

✔️ Accepted for publication in Current Oncology

(Topic: machine learning on ePROs to cluster symptoms by cancer type)

    • Consilium App Improves ePRO Monitoring in Immunotherapy

Case report in lung cancer: shared reporting improves comfort and efficiency

📰 Case Reports in Oncology, 2020

🔗 PubMed: 32518544

    • Clinical Trial: Patient-App Improves Symptom Recording

Digital symptom recording enhances patient-doctor interaction in 192 cancer patients

📰 JMIR Cancer, 2021

🔗 PubMed: 33729162

    • Report on Medication Effectiveness in Personalized Medicine

Durable response and tolerability in breast cancer therapy

📰 Case Reports in Oncology, 2021

🔗 PubMed: 32518544

    • Review: ePROs Improve Congruence of Patient- and Clinician-Reported Toxicity

Collaborative monitoring in 224 cancer patients

📰 JMIR, 2021

🔗 PubMed: 33729162

    • HER2-Biosimilar in Breast Cancer (OGIPRO Study)

Real-world ePRO observational trial – 80 patients, 8 centers

📰 Published in JMIR Cancer (2024)

🔗 Article

🔍 kofam Trial Registry


Ongoing Trials and Registries

    • THC-CBD for Nausea, Emesis, Sleeplessness, Pain, Anxiety, Appetite Loss in Cancer Assessed via ePRO

Prospective randomized controlled study – 150 patients, 6 centers

Registry now maintained under Swiss sponsorship

🔗 FMH Medical Registry

    • Efficiency of the “Medidux” Smartphone App for Demission Management in Patients Medicated in Acute Admission Unit (AAU)

Observational study on emergency-related symptom tracking and cost reduction

🔗 ClinicalTrials.gov: NCT06655337

    • Evaluation of the Positive Care Effect of the Digital Health App Consilium Care Oncology

 

Multicenter randomized controlled trial with 520 patients, 40 centers (Germany & Switzerland)

 

🧪 Ongoing trial

 

Ethics Approval: KEK-2022-D0021

Prof. Dr. med. Andreas Trojan

CEO, Chief Medical Officer, Founder

Team and expertise

Products developed by qualified experts

Andreas holds a position as senior oncologist at both, the Brust- and the OnkoZentrum Zürich in Switzerland. Moreover, he is a titular-professor at the medical faculty of the University of Zurich. Treating cancer patients over more than 20 years clearly indicated that the consideration of PROs is key for treatment success. Driven by this conviction Andreas founded Mobile Health AG and started to develop Consilium Care™, an App for patients to capture well-being and therapy side effects. The current large observational study, started in 2018, investigates the efficiency of the “Consilium Care™” smartphone App for detecting symptoms and treatment side effects in cancer patients depending on form of medication application, age and outpatient characteristics.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Individual patient

Doctor

Consilium Care™ platform

1. Patients track their health with Consilium Care™

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation.

3. Treatment plans can be adjusted due to insights

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation.

Mobile Health

Evidence-based care in the real-world

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.